News & Updates
Filter by Specialty:
Upadacitinib delivers sustained PRO improvements in AD
Data presented at AAD 2023 underpin the potential of upadacitinib, a selective Janus kinase inhibitor, to provide long-term improvements in patient-reported outcomes (PROs; skin symptoms, sleep, and quality of life [QoL]) in individuals with moderate-to-severe atopic dermatitis (AD).
Upadacitinib delivers sustained PRO improvements in AD
10 Apr 2023
Preop hypertension, hypercholesterolemia foretell T2DM persistence after metabolic surgery
For patients with obesity and type 2 diabetes mellitus (T2DM) who are scheduled to undergo metabolic surgery, the presence of hypertension and hypercholesterolemia at baseline may predict failure of T2DM remission after the procedure, according to a study.
Preop hypertension, hypercholesterolemia foretell T2DM persistence after metabolic surgery
09 Apr 2023
Valaciclovir suppresses Epstein-Barr virus in COPD patients
Treatment with valaciclovir leads to efficacious suppression of Epstein-Barr virus (EBV), having the potential to reduce the sputum inflammatory cell infiltrate, in patients with chronic obstructive pulmonary disease (COPD), according to data from the EViSCO study.